Trials / Not Yet Recruiting
Not Yet RecruitingNCT06995326
A Study of SGB-3383 in Healthy Subjects
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Suzhou Sanegene Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGB-3383 | SGB-3383 for sc injection, single dose |
| DRUG | SGB-3383-Matching placebo | SC injection, single dose |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2026-08-01
- Completion
- 2027-01-01
- First posted
- 2025-05-29
- Last updated
- 2025-06-03
Source: ClinicalTrials.gov record NCT06995326. Inclusion in this directory is not an endorsement.